X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24531) 24531
Book Review (3907) 3907
Publication (2133) 2133
Conference Proceeding (305) 305
Book Chapter (110) 110
Dissertation (27) 27
Magazine Article (17) 17
Web Resource (10) 10
Newspaper Article (4) 4
Paper (4) 4
Trade Publication Article (3) 3
Book / eBook (2) 2
Data Set (2) 2
Presentation (2) 2
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (20645) 20645
index medicus (17318) 17318
humans (16402) 16402
female (9665) 9665
oncology (8409) 8409
male (8240) 8240
middle aged (6938) 6938
aged (6531) 6531
ophthalmology (6161) 6161
chemotherapy (4898) 4898
angiogenesis inhibitors - therapeutic use (4749) 4749
cancer (4646) 4646
adult (4535) 4535
treatment outcome (4434) 4434
antibodies, monoclonal, humanized (4122) 4122
endothelial growth-factor (4069) 4069
vascular endothelial growth factor a - antagonists & inhibitors (3939) 3939
vascular endothelial growth factor (3879) 3879
angiogenesis (3491) 3491
antineoplastic combined chemotherapy protocols - therapeutic use (3444) 3444
ranibizumab (3036) 3036
aged, 80 and over (2960) 2960
care and treatment (2955) 2955
angiogenesis inhibitors - administration & dosage (2924) 2924
therapy (2749) 2749
retrospective studies (2636) 2636
intravitreal injections (2551) 2551
animals (2502) 2502
antibodies, monoclonal - therapeutic use (2435) 2435
macular degeneration (2424) 2424
metastasis (2206) 2206
colorectal cancer (2098) 2098
antibodies, monoclonal - administration & dosage (2096) 2096
medicine & public health (2077) 2077
antibodies, monoclonal, humanized - administration & dosage (2041) 2041
antibodies, monoclonal, humanized - therapeutic use (2003) 2003
survival (1970) 1970
vegf (1938) 1938
research (1928) 1928
follow-up studies (1807) 1807
antineoplastic agents - therapeutic use (1801) 1801
colorectal neoplasms - drug therapy (1771) 1771
trial (1768) 1768
drug therapy (1755) 1755
surgery (1754) 1754
tomography, optical coherence (1738) 1738
disease-free survival (1697) 1697
prognosis (1670) 1670
pharmacology & pharmacy (1657) 1657
analysis (1654) 1654
angiogenesis inhibitors - adverse effects (1634) 1634
eye diseases (1611) 1611
angiogenesis inhibitors (1594) 1594
tumors (1570) 1570
fluorescein angiography (1527) 1527
patients (1519) 1519
intravitreal bevacizumab (1509) 1509
clinical trials (1464) 1464
colorectal neoplasms - pathology (1395) 1395
visual acuity (1371) 1371
prospective studies (1345) 1345
expression (1328) 1328
bevacizumab - administration & dosage (1301) 1301
genetic structures (1273) 1273
antineoplastic agents (1266) 1266
antineoplastic combined chemotherapy protocols - adverse effects (1253) 1253
fluorouracil (1246) 1246
combination (1244) 1244
cetuximab (1221) 1221
bevacizumab - therapeutic use (1218) 1218
health aspects (1211) 1211
neovascularization (1209) 1209
antimitotic agents (1208) 1208
visual acuity - physiology (1199) 1199
oxaliplatin (1195) 1195
mice (1193) 1193
hematology, oncology and palliative medicine (1180) 1180
paclitaxel (1162) 1162
lung neoplasms - drug therapy (1158) 1158
avastin (1157) 1157
abridged index medicus (1150) 1150
1st-line treatment (1120) 1120
antibodies, monoclonal - adverse effects (1108) 1108
phase-ii trial (1102) 1102
cancer therapies (1086) 1086
neoplasm staging (1077) 1077
efficacy (1073) 1073
irinotecan (1063) 1063
phase-iii trial (1063) 1063
leucovorin (1062) 1062
risk factors (1058) 1058
neoplasm metastasis (1054) 1054
injection (1050) 1050
sense organs (1033) 1033
glioblastoma (1029) 1029
diabetic retinopathy (1027) 1027
article (1025) 1025
combined modality therapy (1011) 1011
vascular endothelial growth factor a - metabolism (1011) 1011
choroidal neovascularization - drug therapy (1004) 1004
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22517) 22517
German (555) 555
French (521) 521
Japanese (385) 385
Korean (279) 279
Spanish (194) 194
Chinese (82) 82
Russian (54) 54
Turkish (54) 54
Czech (49) 49
Polish (48) 48
Hungarian (37) 37
Portuguese (35) 35
Italian (19) 19
Romanian (13) 13
Dutch (8) 8
Slovenian (7) 7
Finnish (5) 5
Croatian (4) 4
Slovak (4) 4
Swedish (4) 4
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Indonesian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Kumar, V and Goel, N
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, ISSN 0275-004X, 01/2019, Volume 39, Issue 1, pp. E5 - E6
Journal Article
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, ISSN 0275-004X, 01/2019, Volume 39, Issue 1, pp. E1 - E2
Journal Article
Journal of Biomedical Materials Research Part A, ISSN 1549-3296, 10/2015, Volume 103, Issue 10, pp. 3148 - 3156
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Eye (Basingstoke), ISSN 0950-222X, 04/2019, Volume 33, Issue 4, pp. 519 - 520
Journal Article
Journal of Neurosurgery, ISSN 0022-3085, 04/2016, Volume 124, Issue 4, pp. 998 - 1007
Journal Article
Journal Article
Investigative Ophthalmology and Visual Science, ISSN 0146-0404, 03/2017, Volume 58, Issue 3, pp. 1856 - 1856
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 262 - 269
We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in... 
Cetuximab bevacizumab | FIRE-3 | Survival dynamics | Metastatic colorectal cancer | 1ST-LINE TREATMENT | LEUCOVORIN | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | CETUXIMAB | ONCOLOGY | RAS MUTATIONS | PHASE-3 TRIAL | IRINOTECAN | KRAS | Bevacizumab - therapeutic use | Proto-Oncogene Proteins p21(ras) - genetics | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cetuximab - therapeutic use | Cetuximab - adverse effects | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Leucovorin - therapeutic use | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Camptothecin - therapeutic use | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Biomarkers, Tumor - genetics | Mutation | Colorectal Neoplasms - pathology | Clinical trials | Metastasis | Analysis | Colorectal cancer | Evaluation | Medical treatment | Colorectal carcinoma | Patients | Survival | Bevacizumab | Metastases | Confidence intervals | Survival analysis | Short courses | Randomization | Motivation | Kinetics | Cancer | Index Medicus
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2015, Volume 17, Issue 11, pp. 1504 - 1513
Journal Article
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article